Characterization of a carbapenem- and colistin-resistant *Enterobacter cloacae* carrying Tn6901 in *bla*_{NDM-1} genomic context

This article was published in the following Dove Press journal:
Infection and Drug Resistance

Tam-Duong Le-Ha¹
Lien Le¹
Hong-Ngoc Le-Vo¹
Mizue Anda²
Daisuke Motooka³
Shota Nakamura³
Linh Khanh Tran¹
Phuong Thi-Bich Tran¹
Tetsuya Iida²
Van Cao¹

¹Department of Immunology and Microbiology, Pasteur Institute in Ho Chi Minh City, Ho Chi Minh City, Vietnam;

²Department of Bacterial Infections, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan; ³Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan

Abstract: We report a clinical strain of *Enterobacter cloacae*, PIMB10EC27, isolated in Vietnam in 2010 that was resistant to 21 of 26 tested antibiotics, including carbapenems (MICs >64 µg/mL) and colistin (MIC >128 µg/mL). The complete genome of strain PIMB10EC27 was sequenced by PacBio RSII and the Illumina Miseq system. Whole-genome analysis revealed that PIMB10EC27 contains a chromosome of the ST513 group (PIMBEC27, length 5,272,177 bp) and two plasmids, pEC27-1 of the IncX3 group (length 62,470 bp) and pEC27-2 of the IncHI1 group (length 84,602 bp). It also revealed that strain PIMB10EC27 carries 15 genes that confer resistance to at least 10 antibiotic groups. Particularly, the insertion of ISKpn19 and Tn6901 into the genomic context of *bla*_{NDM-1} was first identified and described. In another context, amino acid mutations G273D in PmrB and F515S in PmrC were first identified on the chromosome of PIMB10EC27, which may confer resistance to colistin in this strain.

Keywords: *bla*_{NDM-1}, colistin, *Enterobacter cloacae*, multidrug-resistance, Tn6901

Carbapenems are one of the broad-spectrum groups of β-lactam antibiotics and have been considered the best choice for treatment of infections caused by multi-drug-resistant bacteria,¹ however, the recent increase in the rate of carbapenem resistance has been a cause for concern.² Encoded by the *bla*_{NDM-1} gene, New Delhi metallo-β-lactamase 1 (NDM-1), one of the most active and transmissible carbapenemases among the carbapenem-hydrolyzing β-lactamases, was first characterized by Yong et al in 2009³ and has rapidly spread globally. To date, at least 17 NDM alleles have been characterized⁴ and the Tn125 composite transposon bracketed by two copies of ISAbal25 appears to be the main vehicle for dissemination of the *bla*_{NDM-1} gene.⁵ The lack of new generations of antibiotics has positioned colistin, a decades-old antibiotic, as one of the treatments of last resort against multidrug-resistant bacteria, particularly carbapenem-resistant Gram-negative bacteria.^{6,7} Unfortunately, colistin resistance has been reported and is increasing.^{8–11}

Enterobacter cloacae belongs to the *Enterobacteriaceae* family. These Gram-negative bacteria have been a frequent cause of nosocomial multidrug-resistant bacterial infections in the last decade.^{12,13} Carbapenem-resistant *E. cloacae* has been commonly reported in Vietnam and many other countries in the world.^{14–16} However, colistin resistance in *E. cloacae* has not been reported widely, particularly carbapenemase-producing colistin-resistant *E. cloacae* has very recently been reported from some countries including India,¹⁰ the United States,¹⁷ and China.^{18–20}

Correspondence: Van Cao
167 Pasteur Street, District 3, Ho Chi Minh City, Vietnam
Tel +84 283 820 5131
Fax +84 283 823 1419
Email vancao.pasteur@gmail.com

In this study, the whole genome of a clinical carbapenem- and colistin-resistant *E. cloacae* strain, PIMB10EC27, was sequenced and analyzed for its genetic characteristics that may associate with its resistance phenotypes.

PIMB10EC27 was recovered from the urine of a 72-year-old male patient admitted to Binh Dan Hospital in Vietnam in December 2010 with diagnoses of invasive prostate cancer and urosepsis, he had undergone prostatectomy at the same hospital 15 days earlier. The patient was discharged at the request of the family in a state of acute urinary retention and respiratory failure 4 days after hospitalization. During hospitalization, the patient was treated with meropenem, cefoperazone, sulbactam, clavulanic acid, and amoxicillin, but not with colistin. The strain was isolated as a part of the routine hospital laboratory procedures and identified as *E. cloacae* using a Vitek II kit (BioMérieux, USA).

The in vitro antibiotic susceptibility of PIMB10EC27 was tested by the Kirby-Bauer (KB) method, and the minimum inhibitory concentration (MIC) using the agar dilution method was also determined according to recommendations of the Clinical and Laboratory Standards Institute (CLSI 2018)¹⁹ except for colistin, which was performed with broth microdilution method and interpreted by the guidelines of European Union Committee for Antimicrobial Susceptibility Testing (EUCAST 2019).²⁰ The results showed that PIMB10EC27 was resistant to 21 of 26 tested antibiotics, particularly imipenem (MIC >64 µg/mL), ertapenem (MIC =128 µg/mL), meropenem (MIC =128 µg/mL), and colistin (MIC >128 µg/mL); susceptible to amikacin, levofloxacin nitrofurantoin; and showed intermediate resistance to ciprofloxacin, ofloxacin (Table 1).

A Nextera XT DNA Library Prep Kit (Illumina Inc., USA) and SMRTbell Template Prep Kit (Pacific Biosciences, USA) were used to prepare libraries for the whole genome sequencing of PIMB10EC27 using simultaneously the MiSeq System (Illumina Inc.) with MiSeq Reagent Kit v.2 (2×150 cycles), and the PacBio RSII (Pacific Biosciences) together with Sequel Sequencing Kit 2.0 (8 rxn).

In total, 3.8Gb of filtered subreads were obtained from PacBio RSII sequencing platform. Using PacBio's pre-patching program, we obtained 353Mb of 35,932 reads with the sizes of 500–27,847 bp. The pre-assemble reads were further packaged with HGAP program, which yielded a 5,272,177 bp chromosome and two plasmids of 62,318 bp and 84,480 bp. MiSeq data was used for the error correction

Table 1 Antibiotic susceptibility of the *E. cloacae* PIMB10EC27

Antibiotic	Kirby-Bauer method	MIC (µg/mL)
Gentamycin	R	2
Tobramycin	R	
Amikacin	S	
Kanamycin	R	
Piperacillin-tazobactam	R	
Ticarcillin-clavulanic acid	R	
Imipenem	R	>64
Ertapenem	R	128
Meropenem	R	128
Cefuroxime	R	>256
Cefotaxime	R	
Ceftriaxone	R	
Ceftazidime	R	
Ciprofloxacin	I	>256
Levofloxacin	S	
Ofloxacin	I	
Trimethoprim-sulfamethoxazole	R	
Sulfonamide	R	
Aztreonam	R	
Nitrofurantoin	S	
Piperacillin	R	
Chloramphenicol	R	
Tetracycline	R	
Doxycycline	R	
Cefoxitin		
Colistin		

Abbreviations: R, Resistant; S, Sensitive; I, Intermediate.

of PacBio consensus sequences. By integrating these two platforms, we were able to obtain the complete genome which consisted of a chromosome (5,272,177 bp) belonging to the ST513 group and two plasmids, pEC27-1 of the IncX3 group (62,470 bp) and pEC27-2 of the IncHI1 group (84,602 bp) (Figure 1). The complete genome sequence was annotated with NCBI Prokaryotic Genome Annotation Pipeline servers and analyzed by bioinformatics programs or software, including ResFinder 2.1,²¹ MLST,²² Isaga,²³ Galaxy,²⁴ and Plasmid Finder²⁵ for antibiotic resistance genes identification, chromosome classification, sequences of insertion sequence (IS) determination, integrons finding, and plasmids classification, respectively. In total, 15 coding genes conferring resistance to 10 antibiotic groups were found on PIMB10EC27 (Table 2). Among these genes, *bla*_{NDM-1}, *bla*_{SHV-12}, *bla*_{CMH}, *aac*_{(3)-ID}, *strA*, *strB*, *dfpA-14*, *sul2*, *catA2*, and *tet(D)* were associated with resistance

Gene	Description	Resistance mechanism	Antibiotic group/agent
Chromosome			
<i>bla_{CMH}</i>	CMH family class C β -lactamase	Antibiotic inactivation	β -lactams
<i>fosA</i>	FosA/FosA2 family fosfomycin resistance glutathione transferase	Antibiotic inactivation	Fosfomycin
pEC27-1			
<i>bla_{NDM-1}</i>	New Delhi metallo- β -lactamase NDM-1	Antibiotic inactivation	β -lactams
<i>bla_{SHV-12}</i>	Extended-spectrum beta-lactamase SHV-12	Antibiotic inactivation	β -lactams
<i>ble_{MBL}</i>	Bleomycin-resistance protein	Sequestering effect of the bleomycin-binding protein	Bleomycin
pEC27-2			
<i>aac(3)-IId</i>	Aminoglycoside acetyltransferase	Antibiotic inactivation	Aminoglycosides
<i>bla_{LAP-2}</i>	Class A β -lactamase LAP-2	Antibiotic inactivation	β -lactams
<i>bla_{TEM-1B}</i>	Class A broad-spectrum β -lactamase TEM-1	Antibiotic inactivation	β -lactams
<i>catA2</i>	Chloramphenicol acetyltransferase	Antibiotic inactivation	Phenicols
<i>dfrA14</i>	Dihydrofolate reductase	Altered affinity of reductase	Trimethoprim
<i>qnrS1</i>	Quinolone resistance pentapeptide repeat protein	Antibiotic target protection	Quinolones, fluoroquinolones
<i>strA</i>	Aminoglycoside phosphotransferase	Antibiotic inactivation	Aminoglycosides
<i>strB</i>	Aminoglycoside phosphotransferase	Antibiotic inactivation	Aminoglycosides
<i>sul2</i>	Sulfonamide resistant dihydropteroate synthase	Antibiotic target replacement	Sulphonamides
<i>tet(D)</i>	Tetracycline efflux pump	Antibiotic efflux	Tetracyclines

phenotypes of PIMB10EC27. On the other hand *qnrS1* equivalent to the intermediate fluoroquinolone-resistance phenotype of PIMB10EC27 has been proven to reduce the antibiotic susceptibility of bacteria to quinolones or fluoroquinolone.^{26–28} In addition, 160 putative transposase open reading frames (tORFs) were identified in which the number of tORFs located on the chromosome, pEC27-1 and pEC27-2 were 113, 10 and 37, respectively. Antibiotic resistance genes closely located to these transposase sequences may have contributed to the accumulation and increase in the antibiotic resistance of PIMB10EC27. A 1722-bp class 1 integron with gene cassette *dfrA14* flanked by IS6 sequences was also found on plasmid pEC27-2.

We further analyzed the genes in PIMB10EC27 that confer resistance to carbapenem and colistin. As a result, a *bla*_{NDM-1} gene was found on pEC27-1 of PIMB10EC27 along with a *bla*_{SHV-12} and *ble*_{MBL}. A comparison of the nucleotide sequence of pEC27-1 and those of other IncX3 plasmids carrying *bla*_{NDM-1} and *bla*_{SHV-12}, including pKPN5047 (KC311431), pNDM-HF727 (KF976405), pNDM-HN380 (JX104760), and RJA274 plasmid NDM-1 (KF877335) was carried out in order to identify if any unique structure characteristics contributed to the multidrug-resistance of PIMB10EC27. Comparative results of the genomic context surrounding the resistance genes revealed that all of the plasmids had a conserved sequence carrying Δ IS*Aba125*, *bla*_{NDM-1}, *ble*_{MBL}, *trpF*, *dsbC*, *cutA1*, *groES*, *groEL*, and ISCR21 (Figure 2). This conserved sequence is also a Tn125 composite transposon, in which the *bla*_{NDM-1}

gene lies downstream of a truncated IS*Aba125* element that provides the –35 region for the promoter of *bla*_{NDM-1}.²⁹ A 93-bp sequence separates the right-hand inverted repeat of IS*Aba125* from the start codon of *bla*_{NDM-1}, and the deletion of an IS5 was identified in the plasmid pEC27-1. An ISCR21-like element was also found downstream of *bla*_{NDM-1} and it is suggested that this element may be responsible for initial gene capture.⁵ The IS26-bounded region of pEC27-1 containing *ygbI*, *ygbJ*, and *bla*_{SHV-12} was found to be very distinct from the other plasmids. This region carried three copies of IS26, and the local *ygbJ* gene was split into two parts, whereas other plasmids carried only two copies of IS26 and the full *ygbJ* gene. The isolation and reverse with a copy of IS26 in the plasmid pEC27-1 of the 424-bp region of the *ygbJ* gene might propose there is an IS26-mediated re-organization. Interestingly, an insertion of IS*Kpn19* and Tn6901 into the *mpr* gene (encoding zinc metalloproteinase) lying further upstream of *bla*_{NDM-1} was also observed (Figure 2). Belonging to IS*Kra4* family, IS*Kpn19* is 2851 bp in length and has been found to lie downstream of *bla*_{OXA-181} in an IncX3-type plasmid.³⁰ Tn6901, first described in plasmid Rts1 of *Proteus vulgaris*,³¹ is 6.9 kb in length and harbors 6 genes, including a transposase gene (*tnpA*), a resolvase gene (*tnpR*), an alcohol dehydrogenase gene (*adh*), a glyoxalase/bleomycin resistance gene (*glo*), an S-formylglutathione hydrolase gene (*fgh*), and a regulatory protein gene (*frmR*). We report here the first case, to our knowledge, of a 9.8-kb insertion sequence harboring IS*Kpn19* and Tn6901 in the genomic

Figure 2 Genetic context of *bla*_{NDM-1} on IncX3 plasmids pKPN5047, pNDM-HF727, pNDM-HN380, RJA274 plasmid NDM-1, and pEC27-1. Gray shading denotes shared regions of homology: light gray indicates a forward match and dark gray indicates a reverse match. Notably, *ygbJ* is split into two parts, and the IS26-*ygbJ* region is inverted in pEC27-1 relative to the other plasmids. The *mpr* gene in pEC27-1 is interrupted by IS*Kpn19* and Tn6901 insertions. Open reading frames are portrayed by arrows and are colored. Resistance genes are indicated in red arrows, including *bla*_{NDM-1}, *bla*_{SHV-12}, *ble*_{MBL}, *fgh*, *glo*, and *adh*.

context of *bla*_{NDM-1}. This insertion made the genomic context of *bla*_{NDM-1} in PIMB10EC27 more complex with 6 resistance genes, including *adh*, *glo*, *fgh*, *bla*_{NDM-1}, *ble*_{MBL}, and *bla*_{SHV-12}, which may also affect the dissemination and expression of *bla*_{NDM-1}. Further research is required to clarify these assumptions.

Genome analysis was also performed to identify the genes that confer resistance to colistin of PIMB10EC27. In this research, we did not find any *mcr* gene that recently characterized as a novel mobile gene responsible for colistin resistance among Gram negative bacteria.³² In addition, our transformation experiments revealed that none of the plasmids of PIMB10EC27 was associated with colistin resistance (data not shown). In another context, encoding genes involved in the attachment of L-Ara-4N and P-EtN to LPSs of PIMB10EC27, including *phoP*, *phoQ*, *pmrB*, *pmrA*, *pmrC*, *mgrB*, *lpx*, and *arn* were examined, and amino acid replacements G273D in PmrB and F515S in PmrC of PIMB10EC27 were recorded. The role of these mutations in colistin resistance remains to be investigated.

In summary, we successfully constructed the complete genome of multidrug-resistant *E. cloacae* strain PIMB10EC27 carrying the novel genomic context of *bla*_{NDM-1}. To our knowledge, this is the first report in Vietnam of a carbapenemase-producing *E. cloacae* strain that was also resistant to colistin. PIMB10EC27 was isolated from a patient not being treated with colistin and not identified as a case of a plasmid-mediated colistin-resistance mechanism.

In the battle against multidrug-resistant bacteria, particularly carbapenem-resistant bacteria, colistin has been considered to remain effective. In such context, this report of a clinical isolate that is resistant to both colistin and carbapenem raises a high concern over future clinical management and infection control.

Nucleotide sequence accession numbers. The complete nucleotide sequences of PIMB10EC27 have been deposited in GenBank under accession numbers CP020089-CP020091.

(<https://www.ncbi.nlm.nih.gov/nuccore/CP020089.1/>, <https://www.ncbi.nlm.nih.gov/nuccore/CP020090>, <https://www.ncbi.nlm.nih.gov/nuccore/CP020091>).

Abbreviation list

MIC, minimum inhibitory concentration; *E. cloacae*, *Enterobacter cloacae*; CLSI, Clinical and Laboratory Standards Institute; NDM-1, New Delhi metallo- β -lactamase 1; ORF, Open Reading Frame.

Data availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Acknowledgments

We thank Binh Dan Hospital in Ho Chi Minh City, Vietnam for providing the isolated bacteria for the research. We greatly appreciate Dr. James W. Jones for his valuable review. This work was supported by the US Armed Forces Research Institute of Medical Sciences (AFRIMS), the National Institute of Health (NIH), and the Grant for Joint Research Project of the Research Institute for Microbial Diseases, Osaka University.

Author contributions

VC and TI conceived and designed the study. TDLH, PTBT, LL, and LKT collected samples and performed experiments, TDLH, HNLV, PTBT, LL, DM, SN, and MA performed data analysis, TDLH and HNLV wrote the paper. All authors contributed to drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

Dr Tam-Duong Le-Ha reports grants from the US Armed Forces Research Institute of Medical Sciences (AFRIMS), grants from the National Institute of Health (NIH), and grants from the Research Institute for Microbial Diseases, Osaka University, during the conduct of the study. Ms Lien Le reports grants from the US Armed Forces Research Institute of Medical Sciences (AFRIMS), grants from the National Institute of Health (NIH), and grants from the Research Institute for Microbial Diseases, Osaka University, during the conduct of the study. Miss Hong-Ngoc Le-Vo reports grants from US Armed Forces Research Institute of Medical Sciences, grants from National Institute of Health, and grants from Grant for Joint Research Project of the Research Institute for Microbial Diseases, Osaka University, during the conduct of the study. Dr Mizue Anda has nothing to disclose. Dr Daisuke Motooka has nothing to disclose. Dr Shota Nakamura has nothing to disclose. Dr Linh Khanh Tran reports grants from the US Armed Forces Research Institute of Medical Sciences (AFRIMS), grants from the National Institute of Health (NIH), and grants from the Grant for Joint Research Project of the Research Institute for Microbial Diseases, Osaka University, during the conduct of the study. Dr Phuong Thi-Bich Tran reports grants from The US Armed

Forces Research Institute of Medical Sciences (AFRIMS), grants from The National Institute of Health (NIH), and grants from The Research Institute for Microbial Diseases, Osaka University, during the conduct of the study. Dr Tetsuya Iida has nothing to disclose. Dr Van Cao reports grants from the US Armed Forces Research Institute of Medical Sciences (AFRIMS), grants from the National Institute of Health (NIH), and grants from the Research Institute for Microbial Diseases, Osaka University, during the conduct of the study.

References

- Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. *Antimicrob Agents Chemother*. 2011;55(11):4943–4960. doi:10.1128/AAC.00296-11
- Nordmann P, Poirel L. The difficult-to-control spread of carbapenemase producers among *Enterobacteriaceae* worldwide. *Clin Microbiol Infect*. 2014;20. doi:10.1111/1469-0691.12742
- Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in *Klebsiella pneumoniae* sequence type 14 from India. *Antimicrob Agents Chemother*. 2009;53(12):5046–5054. doi:10.1128/AAC.00774-09
- Liu Z, Wang Y, Walsh TR, et al. Plasmid-mediated novel bla_{NDM-17} gene encoding a carbapenemase with enhanced activity in a sequence type 48 *Escherichia coli* strain. *Antimicrob Agents Chemother*. 2017;61(5). doi:10.1128/AAC.02233-16.
- Poirel L, Bonnin RA, Boulanger A, Schrenzel J, Kaase M, Nordmann P. Tn125-related acquisition of bla(NDM)-like genes in *Acinetobacter baumannii*. *Antimicrob Agents Chemother*. 2012;56(2):1087–1089. doi:10.1128/AAC.05620-11
- American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med*. 2005;171(4):388–416. doi: 10.1164/rccm.200405-644ST.
- Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. *Clin Infect Dis*. 2005;40(9):1333–1341. doi:10.1086/429323
- Catry B, Cavalieri M, Baptiste K, et al. Use of colistin-containing products within the European Union and European Economic Area (EU/EEA): development of resistance in animals and possible impact on human and animal health. *Int J Antimicrob Agents*. 2015;46(3):297–306. doi:10.1016/j.ijantimicag.2015.06.005
- Bialvaei AZ, Kafil HS. Colistin, mechanisms and prevalence of resistance. *Curr Med Res Opin*. 2015;31(4):707–721. doi:10.1185/03007995.2015.1018989
- Manohar P, Shanthini T, Ayyanar R, et al. The distribution of carbapenem- and colistin-resistance in Gram-negative bacteria from the Tamil Nadu region in India. *J Med Microbiol*. 2017;66(7):874–883. doi:10.1099/jmm.0.000508
- Poirel L, Jayol A, Nordmann P. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. *Clin Microbiol Rev*. 2017;30(2):557–596. doi:10.1128/CMR.00064-16
- Musil I, Jensen V, Schilling J, Ashdown B, Kent T. *Enterobacter cloacae* infection of an expanded polytetrafluoroethylene femoral-popliteal bypass graft: a case report. *J Med Case Rep*. 2010;4:131. doi:10.1186/1752-1947-4-131
- Sanders WE, Sanders CC. *Enterobacter spp.*: pathogens poised to flourish at the turn of the century. *Clin Microbiol Rev*. 1997;10(2):220–241.
- Lee Y, Choi H, Yum JH, et al. Molecular mechanisms of carbapenem resistance in *Enterobacter cloacae* clinical isolates from Korea and clinical outcome. *Ann Clin Lab Sci*. 2012;42(3):281–286.
- Kiedrowski LM, Guerrero DM, Perez F, et al. Carbapenem-resistant *Enterobacter cloacae* isolates producing KPC-3, North Dakota, USA. *Emerg Infect Dis*. 2014;20(9):1583–1585. doi:10.3201/eid2009.140344
- Wilson BM, El Chakhtoura NG, Patel S, et al. Carbapenem-resistant *Enterobacter cloacae* in patients from the US Veterans Health Administration, 2006–2015. *Emerg Infect Dis*. 2017;23(5):878–880. doi:10.3201/eid2305.162034
- Norgan AP, Freese JM, Tuin PM, Cunningham SA, Jeraldo PR, Patel R. Carbapenem- and colistin-resistant *Enterobacter cloacae* from Delta, Colorado, in 2015. *Antimicrob Agents Chemother*. 2016;60(5):3141–3144. doi:10.1128/AAC.03055-15
- Huang L, Wang X, Feng Y, Xie Y, Xie L, Zong Z. First identification of an IMI-1 carbapenemase-producing colistin-resistant *Enterobacter cloacae* in China. *Ann Clin Microbiol Antimicrob*. 2015;14:51. doi:10.1186/s12941-015-0113-1
- Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Susceptibility Testing – 28th Edition*. CLSI Document M100-28. Wayne (PA): CLSI; 2018.
- European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical Breakpoints – bacteria v9.0. 2019. Available from: http://www.eucast.org/clinical_breakpoints/. Accessed January 18, 2019.
- Zankari E, Hasman H, Cosentino S, et al. Identification of acquired antimicrobial resistance genes. *J Antimicrob Chemother*. 2012;67(11):2640–2644. doi:10.1093/jac/dks261
- Belén A, Pavón I, Maiden MCJ. Multilocus sequence typing. *Methods Mol Biol (Clifton, NJ)*. 2009;551:129–140.
- Varani AM, Siguier P, Gourbeyre E, Charneau V, Chandler M. ISSaga is an ensemble of web-based methods for high throughput identification and semi-automatic annotation of insertion sequences in prokaryotic genomes. *Genome Biol*. 2011;12(3):R30. doi:10.1186/gb-2011-12-3-r30
- Afgan E, Baker D, van den Beek M, et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update. *Nucleic Acids Res*. 2016;44(W1):W3–W10. doi:10.1093/nar/gkw343
- Carattoli A, Zankari E, Garcia-Fernandez A, et al. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother*. 2014;58(7):3895–3903. doi:10.1128/AAC.02412-14
- Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. *Lancet*. 1998;351(9105):797–799. doi:10.1016/S0140-6736(97)07322-4
- Tran JH, Jacoby GA, Hooper DC. Interaction of the plasmid-encoded quinolone resistance protein Qnr with *Escherichia coli* DNA gyrase. *Antimicrob Agents Chemother*. 2005;49(1):118–125. doi:10.1128/AAC.49.1.118-125.2005
- Jacoby GA, Walsh KE, Mills DM, et al. qnrB, another plasmid-mediated gene for quinolone resistance. *Antimicrob Agents Chemother*. 2006;50(4):1178–1182. doi:10.1128/AAC.50.4.1178-1182.2006
- Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P. Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant *Escherichia coli* in Australia. *Antimicrob Agents Chemother*. 2010;54(11):4914–4916. doi:10.1128/AAC.00878-10
- Zurfluh K, Poirel L, Nordmann P, Klumpp J, Stephan R. First detection of *Klebsiella variicola* producing OXA-181 carbapenemase in fresh vegetable imported from Asia to Switzerland. *Antimicrob Resist Infect Control*. 2015;4(1):38. doi:10.1186/s13756-015-0080-5
- Murata T, Ohnishi M, Ara T, et al. Complete nucleotide sequence of plasmid Rts1: implications for evolution of large plasmid genomes. *J Bacteriol*. 2002;184(12):3194–3202.
- Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis*. 2016;16(2):161–168. doi:10.1016/S1473-3099(15)00424-7

Infection and Drug Resistance

Dovepress

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/infection-and-drug-resistance-journal>